Pharmaceutical and medical technology giant Johnson & Johnson on Tuesday announced a landmark agreement in principle to resolve the vast majority of its remaining ovarian talc litigation. The proposed settlement carries a $5.5 billion financial commitment and is structured to bring a final, efficient close to a sprawling 15-year legal chapter.
The deal follows a critical legal milestone in the federal Multi-District Litigation and related state court proceedings. Following hearings that scrutinized the underlying science, plaintiffs in two key bellwether trials withdrew their specific-causation experts.
Consequently, the MDL court ordered plaintiffs to show cause why the remaining claims should not be dismissed for an inability to prove that the company’s talc products directly caused specific instances of ovarian cancer. While maintaining its position that the claims lack scientific backing, company leadership noted that a negotiated resolution provides definitive closure.
“While we are confident the company would have ultimately prevailed with further litigation, as it has in the vast majority of cases tried to date, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” Erik Haas, Worldwide Vice President of Litigation at Johnson & Johnson, said.
Key terms of the proposed agreement
To take effect, the comprehensive settlement is subject to specific criteria, most notably:
- Participation threshold: The agreement is conditioned on the express participation of lead plaintiff firms representing at least 95% of the remaining ovarian talc claims.
- Structured payouts: The $5.5 billion commitment will be executed through per-claim payments, with an initial installment of no more than $3 billion scheduled for 2027 and no further payments required before 2028.
- Scope: The deal addresses the remaining roughly 76,000 ovarian talc claims, effectively complementing prior resolutions that successfully closed out roughly 95% of filed mesothelioma lawsuits, state consumer protection claims, and supplier disputes.
Johnson & Johnson emphasized that decades of independent global medical research and regulatory evaluations continue to support the safety of cosmetic talc, asserting it is asbestos-free and does not cause cancer.
Having previously discontinued talc-based baby powder globally in 2023 and successfully separated its consumer health business, Kenvue (while retaining all North American talc liabilities and indemnification costs), this settlement clears the operational horizon. The company aims to direct its full energy toward advancing its core sectors in Innovative Medicine and MedTech.
